Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.
In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
Christophe Quéva, CEO of Egle Therapeutics
About Egle Therapeutics
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
For more information www.egle-tx.com
About France 2030
✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.
✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).
✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.
✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.
For more information: france2030.gouv.fr | @SGPI_avenir
About the Call for Projects “Innovations in Biotherapies and Bioproduction”
The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.
About Bpifrance
Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.
Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.
For more information: www.bpifrance.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ravenna Becomes the First Colourblind-Friendly City in Italy: Event and New EnChroma Glasses Donation18.3.2025 18:29:00 EET | Press release
Tomorrow, March 19, 2025, at 4:30 PM, the conference "How Colourblind People See" will be held at the Martini Hall of MAR – Ravenna’s Museum of Art. This event is dedicated to raising awareness about colour blindness and the challenges of colour perception. Speakers will include Stefano De Pietro, President of the Italian Association "How Colourblind People See", and Sandor Breznay, President of the Breznay-Ganoczy Foundation (Agno, Switzerland) and the Paolina Brugnatelli Foundation (Milan). Colour blindness affects approximately 1 in 12 men and 1 in 200 women, with over 300 million people worldwide experiencing this condition—2.5 million in Italy. While those with normal colour vision can distinguish over a million shades, individuals with colour vision deficiency see only about 10% of those hues. As a result, colours may appear dull or even indistinguishable. This initiative aims to increase public awareness and make cultural and educational experiences more accessible for those wit
Accelera hosts Spanish Prime Minister and industry leaders for tour and meeting at Guadalajara electrolyzer facility18.3.2025 18:10:00 EET | Press release
Accelera™ by Cummins, the zero-emissions business segment of Cummins Inc. [NYSE: CMI], hosted Spanish Prime Minister Pedro Sánchez and other government officials at its state-of-the-art electrolyzer manufacturing facility in Guadalajara, Castilla-la Mancha, Spain. The visit highlighted Accelera's important role in enabling the European Union (EU) and Spain's energy transition toward a sustainable future. Following Prime Minister Sánchez’s visit, Accelera held a meeting with top industry executives to explore opportunities for advancing the Spanish green hydrogen market together. The Government of Spain is committed to the green transition, with green hydrogen as one of its pillars. The decisive policies promoted by the Executive have allowed 20% of green hydrogen projects in Europe to be promoted in Spain. Prime Minister Sánchez toured the 260,000 square-foot proton exchange membrane (PEM) electrolyzer manufacturing facility, one of the largest in Spain, and met with Accelera employees
Japan’s Cross-border E-Commerce “WAFUU.COM” Adds Shipping to 37 New Countries18.3.2025 17:05:00 EET | Press release
QRESTIA Inc. (Headquarters: Shibuya, Tokyo; President & CEO: Hidemasa Fukada) is pleased to announce that WAFUU.COM, its cross-border e-commerce site, has expanded its shipping network to an additional 37 countries, bringing the total to 107. 1. Overview WAFUU.COM offers a wide range of Japanese products, from traditional crafts to the latest trends. Previously shipping to 70 countries, the site has now added the 37 destinations listed below. It also continues to support 21 languages, ensuring a safe and comfortable shopping experience for users worldwide. Newly supported countries/regions (37): Argentina, Uruguay, Ecuador, El Salvador, Guadeloupe, Cuba, Costa Rica, Colombia, Jamaica, Chile, Trinidad and Tobago, Panama, Paraguay, Barbados, French Guiana, Venezuela, Peru, Honduras, Martinique, Algeria, Uganda, Ethiopia, Ghana, Côte d’Ivoire, Djibouti, Zimbabwe, Tunisia, Togo, Nigeria, Botswana, Mauritius, Morocco, Rwanda, Réunion, South Africa, Bangladesh,Ukraine 2. About WAFUU.COM WAFU
TXOne Networks Simplifies OT Security with Major Update to Endpoint Solution, Stellar18.3.2025 17:00:00 EET | Press release
TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, announced Version 3.2 of its Stellar solution, further enhancing its capabilities from endpoint protection to more comprehensive detection and response in operational technology (OT) environments. Stellar simplifies the journey into threat hunting and detection while overcoming the limitations of traditional information technology (IT) endpoint detection and response (EDR) solutions, which can disrupt OT operations and productivity. Purpose-built for OT environments, Stellar ensures effective security without compromising system stability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318210570/en/ “We have observed that alert fatigue, which is common to EDR solutions, can be even more severe in OT security, with security teams feeling overwhelmed by warnings due to the lack of contextual information about OT devices,” said Dr. Terence Liu, Chief Executiv
Laserfiche Announces 2025 Run Smarter® Award Winners18.3.2025 16:00:00 EET | Press release
Laserfiche — a leading enterprise platform that helps organizations manage their most critical content and workflows — today announced the winners of the 2025 Laserfiche Run Smarter® Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318932755/en/ The awards honor individuals and organizations that yield exceptional business results using Laserfiche. From a state department that revolutionized how it protects the environment to an insurance agency that leapt into action after a hurricane: The winners enhance productivity, foster innovative processes and improve lives with Laserfiche technology. “These honorees are champions of the employee and customer experience,” said Karl Chan, CEO of Laserfiche. “They are leading their industries in transforming how they work using Laserfiche. We are delighted to celebrate their remarkable achievements.” Congratulations to the 2025 Run Smarter Award winners: Angela Goerner, direct
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom